{"product_id":"exelixis-swot-analysis","title":"Exelixis SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExelixis shows strong oncology focus and a proven commercial drug in cabozantinib, but faces concentration risk and patent\/litigation pressures; its pipeline and strategic collaborations offer growth levers while competition and pricing remain threats. Purchase the full SWOT analysis for a detailed, editable report and Excel tools to plan, pitch, or invest with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeep oncology specialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFounded in 1994, Exelixis’ singular oncology focus concentrates scientific, clinical and commercial expertise around tumor biology, trial design and KOL networks, yielding clear learning-curve advantages.\u003c\/p\u003e\n\u003cp\u003eThat specialization underpins Cabometyx (cabozantinib), Exelixis’ flagship oncology asset first FDA-approved in 2016 for RCC and expanded into HCC in 2019, improving probability of success in targeted indications.\u003c\/p\u003e\n\u003cp\u003eDeep oncology focus also enables tighter prioritization and efficient resource allocation across core cancer programs, accelerating development timelines and commercialization efforts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeted therapy and immunotherapy capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEmphasis on targeted agents and immuno-oncology aligns with precision medicine trends—targeted\/IO drugs drove \u0026gt;50% of oncology approvals in 2023–24 and remain the fastest-growing segment. Exelixis leverages this with \u0026gt;30 active combination trials as of mid‑2025, aiming at biomarker-defined populations where differentiated efficacy\/tolerability improves outcomes. This pipeline positioning sustained relevance across evolving standards and supported ~ $1.3B net product sales in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D engine oriented to unmet needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExelixis concentrates R\u0026amp;D on indications with high unmet need, leveraging its cabozantinib franchise (Cabometyx approved in \u0026gt;30 countries) and next‑gen programs to target gaps in RCC, HCC and rare tumors. Focusing on unmet needs enables regulatory acceleration (FDA priority review ~6 months; orphan drug exclusivity 7 years) and supports premium pricing and payer receptivity. This targeted approach improves physician adoption and can build durable moats in select indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization experience in oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExelixis leverages commercialization experience in oncology to shorten the path from approval to uptake, evidenced by marketed cabozantinib indications in renal cell carcinoma, hepatocellular carcinoma and medullary thyroid cancer. Established relationships with oncologists, treatment centers and payers drive faster access and reimbursement. A dedicated field force and medical affairs team support label education and real-world evidence generation, strengthening lifecycle management for approved therapies.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThree approved oncology indications: RCC, HCC, MTC\u003c\/li\u003e\n\u003cli\u003eCommercial infrastructure: national field force + medical affairs\u003c\/li\u003e\n\u003cli\u003eFaster payer engagement and RWE programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartnering and combination potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnering amplifies Exelixis core oncology portfolio by enabling IO plus targeted-agent combinations that can de-risk development, share costs, and broaden indications; by 2024 Exelixis maintained multiple active collaborations to access external pipelines and accelerate time-to-proof. This strategy expands scientific optionality and can materially increase total addressable market.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDe-risks trials \u0026amp; shares costs\u003c\/li\u003e\n\u003cli\u003eAccess to external pipelines\u003c\/li\u003e\n\u003cli\u003eSpeeds time-to-proof, expands TAM\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology focus driving \u003cstrong\u003e$1.3B\u003c\/strong\u003e sales, \u0026gt;30 combo trials, 30+ countries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExelixis' singular oncology focus concentrates expertise in tumor biology, trial design and KOL networks, accelerating learning curves.\u003c\/p\u003e\n\u003cp\u003eCabometyx (cabozantinib) is a proven commercial engine, driving ~ $1.3B net product sales in 2024 and approvals in RCC, HCC and MTC.\u003c\/p\u003e\n\u003cp\u003eFocused R\u0026amp;D and partnerships support \u0026gt;30 active combination trials (mid‑2025) and global approval in \u0026gt;30 countries, boosting TAM and payer access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 sales\u003c\/td\u003e\n\u003ctd\u003e$1.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved indications\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombo trials (mid‑2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries approved\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Exelixis, outlining internal strengths and weaknesses and external opportunities and threats that shape its oncology-focused growth, competitive position, and strategic risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise Exelixis SWOT matrix for fast alignment of R\u0026amp;D and commercial strategy, relieving analysis bottlenecks and enabling quick stakeholder buy-in.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue concentration risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDependence on a limited number of oncology assets—chiefly cabozantinib (CABOMETYX), which drives the bulk of Exelixis product revenue—heightens revenue volatility; any competitive displacement, safety signal, or reimbursement cut can materially dent sales. Concentration limits bargaining power with payers and distributors, and diversification across new molecules and indications has progressed slowly, keeping commercial risk elevated.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh R\u0026amp;D burn and long timelines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh R\u0026amp;D burn and long timelines: oncology Phase II\/III programs commonly cost tens to hundreds of millions and industry analyses show about 40% of trials incur delays over 6 months due to enrollment or protocol amendments, creating sustained cash needs and milestone risk. Extended timelines raise the probability of competitor readouts eroding value before Exelixis reaches inflection points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical and regulatory uncertainty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTargeted and IO programs at Exelixis face risk of inconclusive endpoints or unexpected safety signals that can trigger larger datasets or post-marketing commitments from regulators; FDA standard review is ~10 months (6 months priority) while EMA centralized review targets 210 days, creating sequencing variability across geographies. This regulatory uncertainty can materially disrupt forecast visibility and valuation for the company.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited breadth beyond oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eExelixis remains heavily concentrated in oncology, with Cabometyx and related programs driving the majority of product sales as reported in the companys FY2024 filings, narrowing diversification benefits and exposing revenue to oncology-specific reimbursement or guideline shifts. Macro or policy shocks targeting cancer drug pricing or approval pathways would disproportionately affect cash flow and valuation. Limited non-oncology assets constrain platform repurposing and make achieving portfolio balance harder.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eFY2024: majority of revenue from oncology products (Cabometyx-led)\u003c\/li\u003e\n\u003cli\u003eHigh single-area exposure increases regulatory\/payer risk\u003c\/li\u003e\n\u003cli\u003eFewer adjacent‑disease repurposing opportunities\u003c\/li\u003e\n\u003cli\u003eHarder to balance portfolio without non-oncology assets\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and supply complexities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOncology therapeutics demand strict quality and uninterrupted supply; scale-up, CMC changes or reliance on CDMOs can create bottlenecks that risk drug shortages and revenue disruption for Exelixis. Maintaining redundancy, regulatory compliance and inventory buffers raises operating costs and complexity, pressuring margins and launch timelines.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupply-chain fragility\u003c\/li\u003e\n\u003cli\u003eHigh CMC costs\u003c\/li\u003e\n\u003cli\u003eThird-party dependency\u003c\/li\u003e\n\u003cli\u003eShortage→revenue risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration risk: \u003cstrong\u003e\u0026gt;50%\u003c\/strong\u003e FY24 sales; trial delays and CDMO supply strain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConcentration risk: Cabometyx drives the majority of FY2024 product revenue (\u0026gt;50%), leaving sales exposed to competitive, safety or reimbursement shocks. High R\u0026amp;D intensity and long oncology trial timelines (≈40% of trials delayed \u0026gt;6 months) create sustained cash needs and milestone risk. Supply-chain and CMC reliance on CDMOs raise shortage and margin pressures.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCabometyx share FY2024\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrials delayed \u0026gt;6 months\u003c\/td\u003e\n\u003ctd\u003e≈40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA review (std\/priority)\u003c\/td\u003e\n\u003ctd\u003e≈10 months \/ 6 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEMA centralized review\u003c\/td\u003e\n\u003ctd\u003e210 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eExelixis SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document for Exelixis you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report and reflects the same structured, editable content included in the download. Buy now to unlock the complete, detailed version immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabel expansions and new indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExtending cabozantinib and other assets into additional tumor types (approved in RCC, HCC, DTC) increases revenue per molecule by capturing new indications and earlier lines of therapy, which historically expands patient share. Orphan and niche indications can use accelerated\/priority pathways and confer seven-year US market exclusivity, allowing streamlined access and pricing leverage. Each new label enhances durability versus competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCombination regimens with IO and targeted agents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCombining cabozantinib with immune checkpoint inhibitors can deepen responses and overcome resistance, with trials reporting objective response rates rising from about 20% with monotherapy to ~40% in some combinations. Partnerships with PD‑1\/PD‑L1 agents could unlock new standards of care and justify premium pricing and wider guideline inclusion. This strategy multiplies addressable populations across indications, potentially doubling market opportunity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiomarker-driven precision medicine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBiomarker-driven precision medicine enables tighter patient selection and has yielded over 20% higher response rates in biomarker-selected oncology cohorts, boosting Exelixis products' clinical impact. Companion diagnostics support reimbursement and adoption, with diagnostic-linked therapies receiving faster market access in many payers. Targeting precision subsets reduces direct competition and has driven multiple accelerated approvals, strengthening differentiation and health-economic value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic expansion and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEx-US approvals for Cabometyx (cabozantinib) in the EU and Japan extend commercial life and helped drive Exelixis net product sales of roughly $1.6B in 2024; reimbursement wins in major markets can delay generic erosion. Local licensing and distribution partnerships speed market entry and scale, while tailored health-economic dossiers improve payer uptake by demonstrating cost-effectiveness. As oncology infrastructure grows, emerging markets offer incremental volume upside.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEx-US approvals: EU, Japan\u003c\/li\u003e\n\u003cli\u003e2024 net product sales: ~ $1.6B\u003c\/li\u003e\n\u003cli\u003eLocal partnerships: faster access\/distribution\u003c\/li\u003e\n\u003cli\u003eHEOR dossiers: better payer decisions\u003c\/li\u003e\n\u003cli\u003eEmerging markets: incremental volume as care expands\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness development and in-licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAcquiring or in-licensing assets fills pipeline gaps and diversifies risk by adding complementary mechanisms and indications. Early-stage deals provide optionality with manageable capital outlay and upside if programs de‑risk. Late-stage or near-term assets can smooth revenue cliffs while strategic BD builds a multi-asset oncology franchise.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePipeline gap filling\u003c\/li\u003e\n\u003cli\u003eLow-cost optionality via early-stage deals\u003c\/li\u003e\n\u003cli\u003eRevenue smoothing from late-stage in-licensing\u003c\/li\u003e\n\u003cli\u003eMulti-asset oncology franchise\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpand TKI into earlier lines and PD‑1 combos: \u003cstrong\u003e$1.6B\u003c\/strong\u003e, ORR \u003cstrong\u003e~20→40%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExtending cabozantinib into additional indications and earlier lines boosts revenue per molecule and durability; combo trials with PD‑1 agents raised ORR from ~20% (mono) to ~40% in some studies. 2024 net product sales were ~ $1.6B; EU and Japan approvals expand ex‑US lifetime. In‑licensing fills pipeline gaps and smooths revenue cliffs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew indications\u003c\/td\u003e\n\u003ctd\u003eRevenue\/label durability\u003c\/td\u003e\n\u003ctd\u003e$1.6B sales 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombos\u003c\/td\u003e\n\u003ctd\u003eHigher ORR\u003c\/td\u003e\n\u003ctd\u003e~20%→~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense competitive landscape\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe oncology field is crowded with big pharma and nimble biotechs competing in a global market valued at roughly $200 billion in 2023, increasing pressure on Exelixis to defend share. Rapid clinical readouts can pre-empt market entry or change standards of care, shortening time-to-revenue windows. Me-too entrants compress pricing and margin, while each new approval raises the differentiation bar and commercial hurdle rates for Exelixis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePricing and reimbursement pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePayers are tightening oncology formularies and increasingly demand real-world outcomes evidence, squeezing Exelixis as coverage criteria become stricter. Policy shifts and reference pricing in several markets are compressing margins and pressuring list-to-net price erosion. HTA bodies in cost-sensitive countries often restrict access or require price concessions, and scrutiny now extends to the cumulative cost of combination regimens, raising reimbursement risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent cliffs and generics\/biobetters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExpiry of key exclusivities for cabozantinib products invites generics and biobetters into core markets; Cabometyx represented over half of Exelixis product revenue in 2024, raising exposure to loss of exclusivity. Even incremental biobetter or combination innovations can materially erode share if clinically superior. Ongoing patent litigation creates timeline uncertainty, and lifecycle management strategies (label expansions, combos) may not fully offset market erosion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial failures or safety signals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eClinical trial failures or safety signals can halt Exelixis programs and erode confidence in its cabozantinib platform; 2024 revenue stood near $1.27B, raising stakes for programme disruptions.\u003c\/p\u003e\n\u003cp\u003eSerious safety events may force label restrictions or regulatory actions, reducing uptake and investor\/partner interest and increasing opportunity cost as R\u0026amp;D resources are reallocated.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory risk\u003c\/li\u003e\n\u003cli\u003eRevenue exposure ~$1.27B (2024)\u003c\/li\u003e\n\u003cli\u003ePartnering\/market confidence\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D opportunity cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational and supply chain disruptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManufacturing deviations, API shortages, or vendor failures can interrupt supply of cabozantinib, forcing batch holds and hurting access in time-sensitive oncology settings; regulatory inspections may impose costly remediation and reporting burdens; geopolitical or logistics shocks can delay distribution and strain oncology treatment continuity, damaging revenue and reputation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eManufacturing deviations\u003c\/li\u003e\n\u003cli\u003eAPI shortages\/vendor risk\u003c\/li\u003e\n\u003cli\u003eRegulatory remediation costs\u003c\/li\u003e\n\u003cli\u003eGeopolitical\/logistics delays\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology pricing squeeze in $200B market risks companies reliant on single-drug sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntense oncology competition in a ~$200B global market (2023) pressures pricing and share. Payer scrutiny and HTA cost constraints tighten access and compress margins. Cabometyx concentration (\u0026gt;50% of Exelixis revenue) and $1.27B company revenue (2024) amplify exclusivity, regulatory, and supply risks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2023\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket pressure\u003c\/td\u003e\n\u003ctd\u003eGlobal oncology market\u003c\/td\u003e\n\u003ctd\u003e$200B (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue concentration\u003c\/td\u003e\n\u003ctd\u003eCabometyx share \/ company rev\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50% \/ $1.27B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097950982492,"sku":"exelixis-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/exelixis-swot-analysis.png?v=1781793870","url":"https:\/\/pestel-analysis.com\/products\/exelixis-swot-analysis","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}